Hair Loss Treatments Research – Page 2 – nicehair.org
Menu

Category Archives: Hair Loss Treatments Research

Pelage PP405 Phase 2/3 AWAKEN Trial Dosing Milestone: First Patient Dosed as Topical Mitochondrial Pyruvate Carrier Inhibitor Advances to Awaken Dormant Hair Follicle Stem Cells in Norwood IV-V Baldness

Research ArticIn a clinical milestone announced on October 14, 2026, Pelage Pharmaceuticals officially dosed the first patient in its landmark Phase 2/3 AWAKEN registration trial (ClinicalTrials.gov Identifier: NCT07819435), advancing its topical first-in-class small molecule, PP405, into late-stage testing for androgenetic alopecia.

ABS-201 Prolactin Receptor Antibody Breakthrough: Generative AI Biologic Halts K15+ Stem Cell Apoptosis to Drive Follicle Terminalization with Zero Systemic Hormone Depletion

In translational ex vivo data presented at the Barcelona Hair Meeting and late-phase clinical updates from the randomized HEADLINE Phase 1/2a trial (ClinicalTrials.gov Identifier: NCT07317544), researchers revealed results for ABS-201—a first-in-class monoclonal antibody engineered via generative AI to block the Prolactin Receptor (PRLR).

Rubedo RLS-1496 Clinical Trial Launch: First-in-Class GPX4 Senolytic Modulator Clears Pathologic Zombie Cells from Miniaturizing Follicle Niches to Outperform Finasteride in Human Scalp Models

In clinical announcements and human ex vivo evidence released by Rubedo Life Sciences, researchers confirmed the clinical entry of RLS-1496—the world’s first-in-class GPX4 (Glutathione Peroxidase 4) senolytic modulator tested specifically for androgenetic alopecia.

NUL-5 Hair Growth Breakthrough: Human Scalp Follicles Stayed in Anagen as Tropoelastin and HGF Reactivated Wnt Signaling

A new human hair-follicle study reports that NUL-5, an experimental blend of tropoelastin and hepatocyte growth factor, prolonged anagen, increased matrix-cell proliferation and restored dermal papilla activity. Here is what the conference data really show, and why it is not yet a proven treatment for hair loss.

MNC-QQ Cell Therapy Hair Regrowth Breakthrough: First-in-Human Trial Reports 78% Terminal Hair Density Surge After One Autologous Scalp Injection Session

A first-in-human open-label study of autologous MNC-QQ cell therapy reported no adverse effects and significant 6-month gains in hair count, density, mass, thickness, and terminal hair density in five men with androgenetic alopecia.

Clascoterone 5% Solution (Breezula) Phase 3 SCALP Results: Topical Androgen Receptor Antagonist Delivers Up to 539% Relative Hair Count Surge Over Placebo with Zero Systemic Endocrine Disruption

In late-phase clinical trial readouts from the pivotal Phase 3 SCALP clinical development program (SCALP 1 and SCALP 2) conducted across 51 medical centers in the United States and Europe, dermatologists and clinical investigators revealed landmark efficacy data for clascoterone 5% topical solution (investigational code CB-03-01 / Breezula).

Sublingual Minoxidil Hair Growth Mechanism: How Under-the-Tongue Delivery May Boost Anagen Without Blocking Testosterone

Sublingual minoxidil may help testosterone-associated pattern hair loss by delivering minoxidil systemically without directly suppressing testosterone or DHT, then relying on follicular sulfotransferase activation, dermal papilla potassium-channel signaling, VEGF, and longer anagen growth.

MLPH Peptide Hair Regrowth Breakthrough: DGIST Study Reveals Erythropoietin-Derived Helix C-1 Molecule Drives IGF-1 Signaling to Elongate Human Hair Shafts with Zero Blood or Hormone Side Effects

In a bioengineering and regenerative medicine breakthrough published in the peer-reviewed medical journal Biomedicine & Pharmacotherapy, a joint research team from DGIST (Daegu Gyeongbuk Institute of Science and Technology) and Kyungpook National University School of Medicine revealed a novel synthetic peptide: MLPH.

Sublingual Minoxidil Hair Regrowth Breakthrough: Testosterone-Treated Transgender Trial Shows +15.7 Hairs/cm2 Midfrontal Gain Without Lowering Testosterone

A new JAAD randomized placebo-controlled trial reports that sublingual minoxidil improved midfrontal hair count in transgender people receiving full-dose testosterone, with no serious adverse events and no change in testosterone concentrations.

MLPH Peptide Hair Growth Mechanism: How EPOR-IGF-1 Signaling May Switch Dermal Papilla Cells Back Into Anagen Mode

MLPH is exciting because it may copy the hair-growth side of erythropoietin without the blood-building side: EPOR activation in dermal papilla cells, ERK/AKT signaling, higher IGF-1 output, longer human hair shafts, and faster anagen entry in mice.

MLPH Peptide Hair Regrowth Breakthrough: DGIST Study Reveals Erythropoietin-Derived Helix C-1 Molecule Drives IGF-1 Signaling to Elongate Human Hair Shafts with Zero Blood or Hormone Side Effects

In a bioengineering and regenerative medicine breakthrough published in the peer-reviewed medical journal Biomedicine & Pharmacotherapy, a joint research team from DGIST (Daegu Gyeongbuk Institute of Science and Technology) and Kyungpook National University School of Medicine revealed a novel synthetic peptide: MLPH.

Deuruxolitinib Hair Regrowth Dose Breakthrough: Phase 2 Trial Shows 8 mg Twice Daily Beats 16 mg Once Daily for Severe Alopecia Areata

A new Phase 2 randomized trial found that splitting deuruxolitinib into 8 mg twice daily produced much stronger scalp hair regrowth than the same 16 mg total daily dose taken once daily in adults with severe alopecia areata.

Microneedling + Minoxidil Mechanism: Why 500–550 Micrometer Needling May Be Too Shallow to Boost Female Hair Regrowth

Microneedling can theoretically boost minoxidil through drug-delivery channels and wound-healing signals, but the new 245-woman trial suggests shallow 500–550 micrometer needling may not trigger enough added follicle biology to beat minoxidil alone.

Microneedling + Minoxidil Hair Growth Reality Check: 245-Woman Trial Finds No Extra Regrowth From 500–550 Micrometer Needling Every 2 or 4 Weeks

A new randomized trial in 245 women with female androgenetic alopecia found that adding shallow 36-needle microneedling every 2 or 4 weeks did not improve hair counts beyond 2% minoxidil alone after 24 weeks.

Topical Dutasteride Hair Growth Mechanism: How Local 5-Alpha-Reductase Blockade May Cut Scalp DHT Without Crashing Systemic Hormones

Topical dutasteride may work by blocking type I and type II 5-alpha-reductase inside the scalp, reducing follicle-level DHT pressure while producing far less serum DHT suppression than oral dutasteride in the Phase II trial.

Topical Dutasteride 0.05% Hair Regrowth Breakthrough: Phase II Trial Reports a 75.5 Hairs/cm2 Density Surge Without the Usual Systemic DHT Crash

A new Phase II randomized trial suggests a novel 0.05% topical dutasteride solution may sharply increase target-area hair count in male pattern hair loss while producing far less systemic DHT suppression than oral dutasteride.

CXCL12–CXCR4 Chemokine Axis in Hair Loss: Groundbreaking Study Reveals How Dihydrotestosterone Hijacks Dermal Fibroblasts to Trigger Inflammatory Follicular Miniaturization Beyond Androgen Receptors Alone

In multi-center investigations and molecular spatial profiling published across peer-reviewed dermatological and immunological journals, researchers uncovered a missing link driving genetic pattern baldness: the fibroblast-derived CXCL12–CXCR4 chemokine axis.

CXCL12–CXCR4 Chemokine Pathway in Hair Loss: How Dihydrotestosterone Reprograms Dermal Fibroblasts to Induce Microenvironmental Miniaturization in Real Research

A major shift in follicular biology moved understanding past the traditional “DHT-only” model of androgenetic alopecia (AGA). Spatial transcriptomics, single-cell RNA sequencing, and human hair organ cultures demonstrated that pattern baldness is not solely a disorder of direct androgen receptor binding inside dermal papilla cells. Instead, dihydrotestosterone (DHT) triggers a secondary, non-hormonal microenvironmental cascade driven by the CXCL12–CXCR4 chemokine axis.

DKK-1 siRNA Hair Growth Mechanism: How CosmeRNA-DKK1 May Release the Wnt/Beta-Catenin Brake That Miniaturizes Follicles

CosmeRNA-DKK1 targets one of the follicle’s most important growth brakes: DKK-1. By silencing this Wnt-blocking signal, topical siRNA may help miniaturized follicles regain stronger dermal papilla, stem-cell, and anagen-growth communication.

Topical DKK-1 siRNA Hair Regrowth Breakthrough: New CosmeRNA-DKK1 Trial Targets the Wnt “Off Switch” Behind Follicle Miniaturization

A new JAAD ahead-of-print randomized trial reports that a topical siRNA formula targeting DKK-1, a Wnt-blocking signal linked to androgen-driven follicle miniaturization, may improve hair density in mild-to-moderate androgenetic alopecia without directly altering systemic hormones.

Latanoprost Acid Hair Growth Mechanism: How FP-Receptor Calcium Signaling May Reawaken Dermal Papilla Cells and Reverse Follicle Miniaturization

Latanoprost acid may boost hair growth by directly activating prostaglandin F2-alpha receptors in the dermal papilla, triggering calcium signals that push miniaturized follicles back toward anagen, multi-hair output, and thicker visible density.

Topical Latanoprost Acid Hair Regrowth Breakthrough: 0.05% FP-Receptor Activator Triggers a 23.5 Hairs/cm2 Density Surge in Women with Pattern Hair Loss

A new randomized pilot trial suggests topical latanoprost acid may awaken female pattern hair follicles through prostaglandin FP-receptor calcium signaling, increasing target-area hair count by up to 23.5 hairs/cm2 in 6 months with no serious adverse events.

Sympathetic Denervation and Immune Privilege Preservation: How Blocking the Neuro-Epithelial “Second Hit” Prevents Hair Follicle Stem Cell Destruction in Real Research

A persistent mystery in autoimmune hair loss (alopecia areata) has been why hair follicles only shed in selective patches or during specific windows of time, despite autoreactive immune cells circulating through the bloodstream constantly. Research published in Nature by investigators at the National Institute of Biological Sciences (NIBS) and Tsinghua University deciphered the mechanism: autoimmune attack requires an indispensable neuro-epithelial second hit.

Autoimmune Hair Loss Breakthrough: Landmark Nature Study Uncovers Two-Hit Neuro-Epithelial Circuit That Shatters Stem Cell Immune Privilege

In a landmark paper published in Nature on September 30, 2026, researchers from the National Institute of Biological Sciences (NIBS) and Tsinghua University deciphered the elusive biological trigger behind autoimmune hair loss: a two-hit neuro-epithelial-immune circuit.

Stemoxydine Hair Regrowth Mechanism: How Prolyl 4-Hydroxylase Inhibition and HIF-1α Hypoxia Signaling Shorten the Kenogen Phase and Restore Dormant Follicles in Real Research

A persistent challenge in treating pattern baldness (androgenetic alopecia) is kenogen—the prolonged, empty interval between the shedding of a telogen hair fiber and the initiation of a new anagen growth cycle. In thinning scalps, follicular units do not instantly vanish; rather, the hair pores sit empty for months to years because the underlying hair follicle stem cells (HFSCs) fail to receive the trigger to re-enter active fiber synthesis.

Pelage PP405 Phase 2/3 AWAKEN Trial Launches: Topical Mitochondrial Pyruvate Carrier Inhibitor Awakens Dormant Hair Follicle Stem Cells in 8 Weeks with Zero Hormonal Suppression

In a clinical milestone registered on ClinicalTrials.gov under protocol NCT06841289 (the AWAKEN trial), Pelage Pharmaceuticals officially advanced its topical first-in-class small molecule, PP405, into registration trials for male and female androgenetic alopecia.

Topical Stemoxydine 5% Hair Regrowth: Clinical Study Proves Hypoxia Mimicry Reverses Kenogen Phase to Trigger New Growth in 97.1% of Patients with Zero Hormonal Disruption

In an interventional clinical trial published in the peer-reviewed Journal of Cosmetic Dermatology, dermatologists and clinical investigators from Tanta University evaluated the therapeutic efficacy and trichoscopic outcomes of topical stemoxydine for hereditary androgenetic alopecia. For decades, the standard medical model for pattern hair loss focused almost exclusively on suppressing systemic dihydrotestosterone (DHT) with 5-alpha reductase inhibitors or expanding blood vessels with minoxidil.

AMP-303 Hair Loss Injection: First-in-Human Clinical Trial Reveals Osteopontin-CD44 Signaling Drives Over 15% Surge in Non-Vellus Hair Count Across Difficult Frontotemporal Zones

In first-in-human randomized clinical trial results and molecular mechanistic updates detailed at international dermatology and hair biology congresses, researchers led by stem cell biologist Dr. Maksim Plikus revealed the clinical efficacy of an investigational intradermal biologic: AMP-303.

DKK3-CKAP4 Hair Loss Breakthrough: Theranostics Cover Study Discovers Novel Fibroimmune Miniaturization Axis Where Targeted Receptor Blockade Restores Follicle Cycling

In a study published in the peer-reviewed biomedical journal Theranostics, molecular dermatologists and genomics researchers from Seoul National University and EpiBiotech uncovered a mechanism explaining why hair follicles shrink and enter dormancy: the DKK3-CKAP4 signaling axis.

WNT5A-ATF3-FOSB Hair Loss Discovery: Advanced Science Study Reveals the Missing Stem Cell Defense Axis That Halts Follicular Miniaturization

In a single-cell genomics discovery published in the peer-reviewed journal Advanced Science, biomedical researchers and molecular dermatologists identified a protective molecular pathway that shields hair follicle stem cells from hormonal destruction: the WNT5A–ATF3–FOSB signaling axis.